Literature DB >> 24409655

Cystatin C as an early marker of diabetic nephropathy in patients with type 2 diabetes.

You La Jeon1, Myeong Hee Kim1, Woo-In Lee1, So Young Kang1.   

Abstract

BACKGROUND: Serum cystatin C has been proposed as an endogenous marker of glomerular filtration rate (GFR) because it shows a correlation with the albumin to creatinine ratio (ACR) in diabetic nephropathy. The aim of this study was to examine the usefulness of cystatin C as an early marker of diabetic nephropathy.
METHODS: From February 2010 to July 2010, 205 outpatients with normo- or microalbuminuria and chronic kidney disease (CKD) of stage III or less were included in this study. Various renal markers including serum cystatin C and ACR were evaluated.
RESULTS: In the ROC curve analysis, cystatin C showed a performance similar to that of serum creatinine. In addition, cystatin C levels increased with increasing CKD stage I to III and from normo- to microalbuminuria and showed a positive correlation with ACR. In a comparison of renal function markers in diabetic patients according to serum cystatin C level, all markers including ACR, serum creatinine, and eGFR showed significant differences between patients with cystatin C level < 1.06 mg/L and those with cystatin C > or = 1.06 mg/L.
CONCLUSIONS: Serum cystatin C is a useful marker of early renal impairment in type 2 diabetic patients because it reflects both a decrease in GFR and elevated ACR.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24409655     DOI: 10.7754/clin.lab.2013.120804

Source DB:  PubMed          Journal:  Clin Lab        ISSN: 1433-6510            Impact factor:   1.138


  6 in total

1.  Biological variation in the serum and urine kidney injury markers of a healthy population measured within 24 hours.

Authors:  Li-Rui Kong; Fei Wei; Da-Hai He; Chao-Qiong Zhou; Hong-Chuan Li; Feng Wu; Yu Luo; Jian-Wei Luo; Qian-Rong Xie; Hai Peng; Yan Zhang
Journal:  BMC Nephrol       Date:  2022-05-24       Impact factor: 2.585

2.  Diagnostic Accuracy of Serum Cystatin C for Early Recognition of Nephropathy in Type 2 Diabetes Mellitus.

Authors:  Suman Sapkota; Saroj Khatiwada; Shrijana Shrestha; Nirmal Baral; Robin Maskey; Shankar Majhi; Lal Chandra; Madhab Lamsal
Journal:  Int J Nephrol       Date:  2021-04-26

3.  The fat mass, estimated glomerular filtration rate, and chronic inflammation in type 2 diabetic patients.

Authors:  Tomáš Šálek; Alena Adamíková; Petr Ponížil
Journal:  J Clin Lab Anal       Date:  2020-02-11       Impact factor: 2.352

4.  Serum cystatin C is closely associated with euthyroid Hashimoto's thyroiditis in adult female Chinese patients.

Authors:  Qiaojing Qin; Min Yang; Wencai Ke; Jinying Zhao; Heyuan Ding
Journal:  J Int Med Res       Date:  2020-08       Impact factor: 1.671

5.  Early Renoprotective Effect of Ruxolitinib in a Rat Model of Diabetic Nephropathy.

Authors:  Mohamed M El-Kady; Reham A Naggar; Maha Guimei; Iman M Talaat; Olfat G Shaker; Maha Saber-Ayad
Journal:  Pharmaceuticals (Basel)       Date:  2021-06-24

6.  Urinary NGAL is a Potential Biomarker for Early Renal Injury in Insulin Resistant Obese Non-diabetic Children

Authors:  Semra Şen; Deniz Özalp Kızılay; Fatma Taneli; Çınar Özen; Pelin Ertan; İpek Özunan; Raziye Yıldız; Betül Ersoy
Journal:  J Clin Res Pediatr Endocrinol       Date:  2021-05-20
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.